AFT Pharmaceuticals' Maxigesic painkiller product is now licensed in 124 countries worldwide, after the formalisation of an agreement with European pharmaceutical group Amicus SA Switzerland in three regions: the Baltics (Latvia, Estonia and Lithuania); Central Eastern Europe (Czech Republic, Hungary, Bulgaria, Romania and Slovakia); and most of the Balkans (Croatia, Slovenia, Serbia, Montenegro, Bosnia and Macedonia).
CEO Dr Hartley Atkinson said the pact exceeded a previously disclosed target to sell Maxigesic in 100 countries.
"This agreement, together with other recent out-licensing agreements, means that Maxigesic is now licensed in 124 countries around the world.
"Getting these agreements in place shows that we are expanding on our planned pathway to deliver on our sales targets," he said.
Currently Maxigesic is sold in eight countries, with some additional launches from this current deal expected to take place in the next 12 months.
"We believe that these markets present good additional potential for Maxigesic as the market, defined by IMS Health for paracetamol and ibuprofen tablet sales for 10 of the 14 countries, is in excess of $220 million," he said.
MEANWHILE AFT said it was now able to confirm that its agreement to out-license Maxigesic to France, Monaco, Andorra and French dependencies (PD 23 May 2017) is with French pharma company Laboratoires Expanscience.
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Jul 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Jul 17
